6000 Shoreline Court
South San Francisco
250 articles with Veracyte, Inc.
Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive
Data Being Presented at CHEST Annual Meeting 2019
Results From Three Studies Presented at CHEST 2019 Suggest Test Increases Physicians’ Confidence in Diagnosis and Can Reduce the Need for Invasive, Risky Procedures
Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m. Eastern time on the same day.
Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019
Veracyte, Inc. (Nasdaq: VCYT) today announced that preliminary clinical data for the company’s noninvasive nasal swab test – the first of its kind – for early detection of lung cancer will be presented at the annual meeting of the American College of Chest Physicians® (CHEST), being held October 18-23 in New Orleans.
Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis
Data support use of Afirma Xpression Atlas to inform surgery and treatment decisions at time of diagnosis
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the following upcoming investor conferences:
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2019 and provided an update on recent business highlights.
Company expands Board with scientific expertise as it advances development of NICUtrition® platform to improve outcomes for preterm infants
7/3/2019Biotech and pharma companies strengthen their executive leadership and board positions.
Expanded Role Strengthens Top Tier of Company’s Executive Leadership Team
Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019.
Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC) available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the original Percepta test
Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment
Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer diagnosis, as compared to the original Afirma test
Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis
Veracyte, Inc. announced new data demonstrating the potential for its Afirma® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients with a rare but aggressive form of thyroid cancer concurrent with diagnosis by the company’s Afirma Genomic Sequencing Classifier (GSC).
The William Blair 39th Annual Growth Stock Conference in Chicago on Wednesday, June 5, 2019, at 2:00 p.m. CDT.
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting
American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago.
Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
Researchers prospectively validated the Percepta GSC on 412 patients with lung nodules who had inconclusive results following bronchoscopy, a common nonsurgical procedure to diagnose lung cancer.
5/17/2019Biopharma companies add new leaders to executive roles and boards of directors.